Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-11

Clinical Trial Update: A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of enzalutamide plus LY3023414 in metastatic prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzalutamide (enzalutamide)
  • LY3023414 (samotolisib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2021-05-11